US Pharma MarketingM&A isn’t just for big pharma. A diverse group of mid-size companies are stepping up dealmaking
Mid-cap American drugmakers, family-owned pharma groups, foundation-governed European players, Japan-based conglomerates, an AI giant and other non-traditional acquirers are peppering the biotech M&A bonanza. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping.
Mid-cap American drugmakers, family-owned pharma groups, foundation-governed European players ...
Source: Endpoints News